Amgen Says 2007 Profits Will Top October Projections
This article was originally published in The Pink Sheet Daily
California biotech cites cost-cutting measures as reason for upgraded earnings per share guidance of $4.30.
You may also be interested in...
Phase III interim results evaluating the anemia drug in cancer setting show more deaths, higher rate of tumor progression.
Amgen says it will present new data to CMS in effort to persuade agency to modify its National Coverage Decision on ESAs.
Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.